Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 3, 1998

View Archived Issues

Teva reviews product pipeline at investors meeting

Company Profile: Versicor

Cardioprotective effects of carvedilol metabolite are less potent than those of the parent drug

Impressive results obtained with C225 in combination with radiotherapy in head and neck cancer

ArQule, Roche Bioscience amend R&D agreement

Watson strengthens R&D capabilities with TheraTech acquisition

Monoamine reuptake inhibitors especially useful for Parkinson's disease

Suntory describes new series for cardio- and cerebrovascular and peripheral circulatory disorders

PTK inhibitors described by Knoll for immune and bone diseases

Preparation and use of TNF-alpha and MMP inhibitors described by Novartis

Synthelabo team presents new agents for incontinence

Hisamitsu, Banyu codevelop new hypolipidemic agent entering phase II

Involvement of central A3 receptors in blood pressure regulation

Mitomycin C derivative shows therapeutic potential in treating bladder carcinoma

Orally active collagenase inhibitor Ro-32-3555 shows potential for osteoarthritis Rx

AlloDerm used to successfully treat rare congenital condition in newborn

Genvir is as effective as Zovirax in genital herpes, with improved dosing

Aastrom awarded second NIH grant to develop production system for UCB stem cells

MGI Pharma: Q3 and nine-month highlights

Tanox Biosystems now Tanox, Inc., Tanox Pharma

Agenerase filed with European regulatory authorities

FDA approves, Immunex launches breakthrough treatment for RA

Diacrin: Q3 1998 highlights

Ribi ImmunoChem withdraws European Melacine application; focuses on U.S. and Canada

FDA committee favors accelerated approval of Ziagen

U.S. grants first approval for GelTex's novel phosphate-binding polymer therapeutic

NAALADase inhibitors now reported to be useful for prostate cancer; patents issued

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 2, 2026.
AND-017 increases RBC and hemoglobin in sickle cell disease
BioWorld Science
Sickle cell disease (SCD) is an inherited hemoglobinopathy caused by a mutation in the gene encoding β-globin that results in hemoglobin S polymerization, red...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...